Drugs Made In America Acquisition II Corp. Ordinary Shares logo

Drugs Made In America Acquisition II Corp. Ordinary Shares

DMII | NASDAQ
Chart Builder DCF Calculator
$10.20
$0.00 (0.00%)
Nov 2, 2026, 11:50 AM ET · Market open
TTM
Period Ending
Q2 2026
Jun 30, 2026
Q1 2026
Mar 31, 2026
Q4 2025
Dec 31, 2025
Q3 2025
Sep 30, 2025
Q2 2025
Jun 30, 2025
Q1 2025
Mar 31, 2025
Cash & Equivalents
174.97K 347.72K 223 315.09K 4.39K 6.99K
Short-Term Investments
n/a n/a n/a n/a n/a n/a
Long-Term Investments
513.88M 509.37M 504.93M 500.11M n/a n/a
Other Long-Term Assets
n/a n/a n/a n/a 101.83K 93.52K
Receivables
n/a n/a n/a 566.27K 2.6K n/a
Inventory
n/a n/a n/a n/a n/a n/a
Other Current Assets
n/a n/a n/a n/a n/a n/a
Total Current Assets
217.82K 351.76K 26.04K 896.36K 11.57K 11.57K
Property-Plant & Equipment
n/a n/a n/a n/a n/a n/a
Goodwill & Intangibles
n/a n/a n/a n/a n/a n/a
Total Long-Term Assets
513.88M 509.37M 504.93M 500.11M 101.83K 93.52K
Total Assets
514.1M 509.73M 504.96M 501.01M 113.4K 105.1K
Account Payables
12.25K 49.17K 99.36K 4.59K n/a n/a
Deferred Revenue
n/a n/a n/a n/a n/a n/a
Short-Term Debt
450K 450K n/a n/a 297.29K 250.1K
Other Current Liabilities
182.32K n/a 201.51K 553.75K n/a n/a
Total Current Liabilities
644.57K 666.29K 300.86K 677.35K 327.51K 281.14K
Long-Term Debt
n/a n/a n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a n/a n/a n/a
Total Long-Term Liabilities
17.5M 17.5M 17.5M 17.5M n/a n/a
Total Liabilities
18.14M 18.17M 17.8M 18.18M 327.51K 281.14K
Total Debt
450K 450K n/a n/a 297.29K 250.1K
Book Value
495.96M 491.56M 487.16M 482.83M -214.12K -176.05K
Book Value Per Share
9.92 9.83 36.66 177.68 -0.01 0
Common Stock
513.88M 509.38M 504.94M 500.11M 1.44K 1.44K
Retained Earnings
-17.93M -17.82M -17.78M -17.28M -249.12K -211.05K
Comprehensive Income
n/a n/a n/a n/a n/a n/a
Shareholders Equity
495.96M 491.56M 487.16M 482.83M -214.12K -176.05K
Total Investments
513.88M 509.37M 504.93M 500.11M n/a n/a

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.